NCT01498029

Brief Summary

The Cartilage Autograft Implantation System (CAIS) is a single-stage procedure in which cartilage is harvested from non-critical regions of articular cartilage, but then immediately morcellated and loaded onto a polymer membrane-scaffold, which is subsequently used to fill the chondral defect. The autograft-membrane composite is fixed to the defect with a biodegradable staple. The investigators aim to evaluate this new technique through a pilot clinical trial involving 36 patients randomized into microfracture and CAIS treatment arms (randomisation ratio 1:2), with a minimum follow-up of 1 year, using both clinical and radiological (magnetic resonance imaging) outcomes. If the results of this pilot trial are successful, the investigators plan to expand the study by recruiting more patients to achieve a suitably-powered trial. Primary hypothesis 1: That functional scores will increase by at least 0.5 SD over pre-operative values, by 1 year following the CAIS procedure Primary hypothesis 2: That articular cartilage height will have a sustained increase of at least 2 mm at 1 year following the CAIS procedure Primary hypothesis 3: That functional scores in the CAIS group will be equivalent or superior to those in the microfracture group

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
36

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Jan 2012

Typical duration for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 7, 2011

Completed
16 days until next milestone

First Posted

Study publicly available on registry

December 23, 2011

Completed
9 days until next milestone

Study Start

First participant enrolled

January 1, 2012

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2013

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2014

Completed
Last Updated

March 21, 2012

Status Verified

December 1, 2011

Enrollment Period

1.9 years

First QC Date

December 7, 2011

Last Update Submit

March 20, 2012

Conditions

Keywords

Cartilage, Articular

Outcome Measures

Primary Outcomes (3)

  • MR Observations of Cartilage Repair Tissue

    The MOCART (MR Observations of Cartilage Repair Tissue) scoring system, which has been well validated in studies of cartilage regeneration techniques, will be used to assess the cartilage repair response

    3 weeks post operative

  • MR Observations of Cartilage Repair Tissue

    The MOCART (MR Observations of Cartilage Repair Tissue) scoring system, which has been well validated in studies of cartilage regeneration techniques, will be used to assess the cartilage repair response

    6 months post-operative

  • MR Observations of Cartilage Repair Tissue

    The MOCART (MR Observations of Cartilage Repair Tissue) scoring system, which has been well validated in studies of cartilage regeneration techniques, will be used to assess the cartilage repair response

    1 year post-operative

Secondary Outcomes (10)

  • Assessment of whole leg mechanical alignment

    1 week prior to surgery

  • Assessment of whole leg mechanical alignment

    1 month post-operative

  • Assessment of whole leg mechanical alignment

    3 month post-operative

  • Assessment of whole leg mechanical alignment

    6 month post-operative

  • Assessment of whole leg mechanical alignment

    1 year post-operative

  • +5 more secondary outcomes

Study Arms (2)

Randomized to Microfracture

ACTIVE COMPARATOR

This group of patients who have been randomised to receive microfracture procedure will be the control group for this study

Procedure: Microfracture

Randomized to CAIS

EXPERIMENTAL

This group of patients who have been randomised to receive the CAIS procedure will be the experimental group for this study

Device: Cartilage Autograft Implantation System (CAIS)

Interventions

MicrofracturePROCEDURE

The microfracture procedure is a standard method for treatment of cartilage damage in which the surgeon will clean the site of your cartilage damage and then will make several small holes in your bone to stimulate your bone marrow with the intention to repair the damaged area with new cartilage tissue

Also known as: Knee, Cartilage, Cartilage Repair
Randomized to Microfracture

The Cartilage Autograft Implantation System (CAIS) is a kit of devices that utilizes morselized autologous hyaline cartilage harvested arthroscopically, affixed onto a synthetic, resorbable implant using a fibrin sealant and implanted in a single surgical procedure. The system is designed as a surgical treatment of damaged knee cartilage using the subject's own healthy cartilage obtained from a non-weight or low weight-bearing region.

Also known as: Knee, Cartilage, Cartilage Repair
Randomized to CAIS

Eligibility Criteria

Age21 Years - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Full-thickness articular cartilage defect on the femoral condyle or trochlea greater than 2 cm2 but less than 10 cm2 in total surface area, following debridement to healthy, stable tissue.
  • Knee mechanical axis malalignment of not more than 3 degrees either varus or valgus from neutral.
  • Patient is fit for surgery.

You may not qualify if:

  • Multifocal disease
  • Tibial plateau lesions
  • Patella lesions
  • Absent menisci or meniscal tears that are unstable and cannot be successfully debrided
  • Non-intact cruciate and collateral ligaments
  • Inflammatory or crystalline arthropathy
  • Systemic medication or conditions likely to compromise chondrocyte cell proliferation and differentiation, e.g. Cushing's syndrome, chemotherapy
  • Morbid obesity (more than 150% ideal body weight)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Singapore General Hospital

Singapore, 169608, Singapore

RECRUITING

MeSH Terms

Conditions

Osteochondritis Dissecans

Interventions

Arthroplasty, Subchondral

Condition Hierarchy (Ancestors)

OsteochondritisBone DiseasesMusculoskeletal Diseases

Intervention Hierarchy (Ancestors)

ArthroplastyOrthopedic ProceduresSurgical Procedures, OperativePlastic Surgery Procedures

Study Officials

  • Shi-Lu Chia, PhD, MBBS

    Singapore General Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Shi-Lu Chia, PhD, MBBS

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 7, 2011

First Posted

December 23, 2011

Study Start

January 1, 2012

Primary Completion

December 1, 2013

Study Completion

December 1, 2014

Last Updated

March 21, 2012

Record last verified: 2011-12

Locations